01235 832023
Source BBC: Welsh patients are taking part in a drugs trial aimed at slowing late-stage multiple sclerosis progression. Experts are looking at how effective a drug is after a smaller study found it may slow down neuronal degeneration. Euryl James, of Llangennith, Gower, said she got involved as a breakthrough could be life-changing. A total… Read more »
Source MS Trust: The European Medicines Agency (EMA) has recommended that Gilenya (fingolimod) must not be taken by pregnant women or women of childbearing age who are not using effective contraception. A review of Gilenya and pregnancy was carried out by the EMA’s safety committee following reports which suggested that babies born to mothers taking Gilenya during pregnancy have… Read more »
100 club winners for July: 1st – Linda Tierney 2nd – Sue Doran 3rd – Steve Lewis Sharing a prize fund of: £77.50 You got to be in it to win it!! Speak to Sue for an application form, only £5 a month!
Source Multiple Sclerosis News Today: A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis(MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational prophylactic (preventive) therapy, possibly intended for all MS… Read more »
Source Medical News Toady: A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses or those whose disease is not active, MediciNova announced. Data from this single Phase 3 study may be used to request marketing approval for ibudilast with the U.S. Food and Drug… Read more »
Source Science Daily: The research shows that projection neurons are damaged by the body’s own immune cells and that this damage could underpin the brain shrinkage and cognitive changes associated with MS. These new findings provide a platform for specific new MS therapies that target damaged brain cells to be developed. Scientists have discovered that… Read more »
Source BioSpace: Multiple sclerosis (MS) is an often-disabling disease of the central nervous system caused by damage to the myelin coating around the nerves. The disease is quite variable but falls into two broad types, relapsing-remitting MS (RRMS), in which patients often go into clinical remission, and progression MS, which does not have remission periods, but… Read more »
Source Multiple Sclerosis News Today: The National Stem Cell Foundation (NSCF) announced the start of a pioneering project to investigate the impact of microgravity on the neurodegeneration associated with primary progressive multiple sclerosis (PPMS) and Parkinson’s disease. The project, a collaboration between the New York Stem Cell Foundation (NYSCF) Research Institute, the Summit for Stem Cell, and investigators with Aspen Neuroscience, will send 3-D… Read more »
Source Multiple Sclerosis News Today: A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS). Importantly, this study was independent of NervGen, a pharmaceutical company that is developing an ISP-like compound — NVG-291 — for the treatment of nerve injury and MS. The study, “Modulating proteoglycan receptor PTPσ using intracellular… Read more »
Source MS Society: Join us for an afternoon with Dr Claire Rice, Neurologist and MS Researcher in Bristol. Claire will give an overview about stem cell treatment for MS including its current role in disease management and research priorities. There will also be the opportunity to meet others and visit information stands The event is free… Read more »